Synthesis of thromboxane A2 analogs. 1980

K C Nicolaou, and R L Magolda, and D A Claremon

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D013931 Thromboxanes Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. Thromboxane

Related Publications

K C Nicolaou, and R L Magolda, and D A Claremon
January 1983, Advances in prostaglandin, thromboxane, and leukotriene research,
K C Nicolaou, and R L Magolda, and D A Claremon
January 1985, Advances in prostaglandin, thromboxane, and leukotriene research,
K C Nicolaou, and R L Magolda, and D A Claremon
February 1987, Drug design and delivery,
K C Nicolaou, and R L Magolda, and D A Claremon
January 1980, Advances in prostaglandin and thromboxane research,
K C Nicolaou, and R L Magolda, and D A Claremon
May 1981, Biochemical and biophysical research communications,
K C Nicolaou, and R L Magolda, and D A Claremon
January 1986, Journal of cardiovascular pharmacology,
K C Nicolaou, and R L Magolda, and D A Claremon
March 1990, Lancet (London, England),
K C Nicolaou, and R L Magolda, and D A Claremon
October 1991, Biochemical and biophysical research communications,
K C Nicolaou, and R L Magolda, and D A Claremon
November 1982, Prostaglandins, leukotrienes, and medicine,
K C Nicolaou, and R L Magolda, and D A Claremon
April 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Copied contents to your clipboard!